Lecanemab And Medicare: Could Better FDA/CMS Communication Improve Coverage Chances?

 
• By Cathy Kelly
  
After Impact On Cognition Finally Demonstrated In Phase III Trial, will FDA, CMS and sponsors have a meeting of the minds? • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

More from Market Access

More from Pink Sheet